01 April 2025
Are you prepared for the launch of the National Lung Cancer Screening Program (NLCSP) from July 2025?
The NLCSP is a screening program using low-dose computed tomography (LDCT) scans to look for lung cancer in high-risk people without any symptoms. The NLCSP aims to achieve better health outcomes for Australians by detecting lung cancer early and reducing deaths from lung cancer.
EMPHN Innovation Series Event: Preparing for the National Lung Cancer Screening Program
As Australia gears up for the launch of the NLCSP in July 2025, EMPHN is excited to invite general practitioners to a unique opportunity to gain valuable insights into the NLCSP implementation.
This event will feature Professor Dorota Gertig, Medical Director of Population Health Solutions at Telstra Health, National Cancer Screening Register, alongside Dr Hashinee Weraduwage, a Melbourne-based General Practitioner and Clinical Editor for HealthPathways Melbourne.
Hear from our experts on how to successfully integrate lung cancer screening into your everyday practice.
Key topics covered:
- An overview of the National Lung Cancer Screening Program
- Eligibility criteria and the screening journey
- The role of the National Cancer Screening Register
- How to integrate and register for the Healthcare Provider Portal
- Local referral pathways for general practices
The event is designed for General Practitioners involved in lung cancer screening and management, offering practical guidance on incorporating screening into daily practice. Register via the event listing below.
Guest speakers:
Professor Dorota Gertig – MB.BS (Hons), MHSc, ScD, FAFPHM, GAICD
Since July 2016, Dorota has been the Medical Director of the National Cancer Screening Register (NCSR), playing a key role in implementation and operations of the Register. She is a public health physician and epidemiologist who completed her medical training at Monash University and has a Doctorate in Epidemiology from the Harvard School of Public Health. Professor Gertig was previously the Medical Director of the Victorian Cervical Cytology Registry and the inaugural Medical Director of NHVPR.
She is a respected leader in cancer screening and a member of several key national and state committees on cervical screening, including the National Quality and Safety Monitoring Committee for the National Cervical Screening Program. Professor Gertig has an international profile in cancer research, including the epidemiology of cervical, breast and ovarian cancers. With more than 120 scientific publications, her primary research focus is on policy relevant research as well as improving participation in cancer screening.
Dr Hashinee Weraduwage – DCH, MBBS, FRACGP
Dr Hashinee Weraduwage graduated from the University of Adelaide and completed her GP training in SA and has been working in Melbourne since 2020. She joined the HealthPathways Melbourne team in April 2024 as a Clinical Editor and has reviewed and updated pathways in Gastroenterology, Obstetrics, Immunisation, Haematology and resources pages for Guide to MBS, Telehealth, and Medicare.
This event is an essential opportunity for general practitioners to prepare for the implementation of the NLCSP and ensure best practices in lung cancer screening.
